Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 63 results for hepatocellular carcinoma

  1. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  5. Past appeals and decisions

    Hearing impairment - cochlear implants 26 November 2008 TA189 Hepatocellular carcinoma (advanced and metastatic)- sorafenib 26 February...

  6. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

    Clinical guideline
    Last updated
    26 April 2023
    View recommendations

    Sections for CG104

  7. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  8. Ex-vivo hepatic resection and reimplantation for liver cancer (IPG298)

    Evidence-based recommendations on ex-vivo hepatic resection and reimplantation for liver cancer. This involves removing the liver from the body, cutting away the diseased tissue, and reimplanting the remaining tumour-free liver into the patient.

    Interventional procedures guidance
    Published
    22 April 2009
    View recommendations

    Sections for IPG298

  9. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued [GID-TA10221]

    Technology appraisal guidance
    Discontinued

  10. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]

    Technology appraisal guidance
    Discontinued

  12. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA330

  13. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    In development [GID-TA11041] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  15. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued [GID-TA10811]

    Technology appraisal guidance
    Discontinued